Ovarian cancer patients with high KRT14 expression have reduced progression-free survival following standard-of-care platinum and taxane-based chemotherapy (HR 1.27; 95% CI 1.07–1.51 p < 0.006) [17]. Here, KRT14 is linked to ovarian carcinoma.